<p>Diabetes Mellitus is an assorted group of metabolic disorders due to the inability of pancreas to secrete insulin or the insensitivity of the cells to insulin. This work has been chosen considering the vital role of aldose reductase inhibitors in Diabetes Mellitus through the polyol pathway. Consequently an effective cont rol is the key to tackle this abnormal condition. In silico analysis for the development of aldose reductase inhibitors were carried out using both phytochemicals and generation of new lead molecules as ligands. The phytochemicals selected for the study were Allicin, Galegine, Rhamnoside, Quercetin, Trigonelline and Ferulic Acid. The lead molecule nucleus finalized were that of chromenes and indole derivatives. The present study included the analysis of parameters relating to proteins such as primary and s econdary structure analysis, subcellular location, analysis of cavities, ADME as well as docking results. Positive results were shown by Allicin, Galegine, Rhamnoside, Quercetin, Trigonelline and Ferulic Acid when compared with the standard drugs like Epalrest and Sorbinil. The lead molecules of chromeme derivative AR2,methyl2,2-dimethyl3-(4oxo-3-phenoxymethyl)-4H-chromrn-8-yl)propanoate and indole derivative AR7, methylidene(([1-(phenoxymethyl)-2,3-dihydro-1H-indol-5yl]oxy))amine screened displayed significant results over the phytochemicals and the standard drugs used. Further in vitro pharmacological activities might prove to be useful to substantiate the results.</p>
cited By 0
V. Vishnu, .T.S, S., and Asha Asokan Manakadan, “In silico strategy for designing of novel chromene and indole derivatives to combat diabetes mellitus”, Research Journal of Pharmaceutical, Biological and Chemical Sciences, vol. 7, pp. 1098-1105, 2016.